A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Informacje na temat projektu

ATx201

Identyfikator umowy o grant: 736508

DOI

10.3030/736508

Projekt został zamknięty

Data podpisania przez KE 11 Lipca 2016

Data rozpoczęcia 1 Sierpnia 2016

Data zakończenia 30 Listopada 2016

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

UNION THERAPEUTICS AS
Denmark

Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)

Okres sprawozdawczy: 2016-08-01 do 2016-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to market.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for the solution in questions. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

The project is designed to demonstrate how the solution in question can contribute to address the medical need in atopic dermatitis and offer a better treatment due to the new mode of action. Early data provides evidence for the potential to change the treatment paradigm of dermatological diseases by providing an innovative and significantly differentiated treatment.

fotolia-114431753-subscription-monthly-m.jpg

boksbillede1.jpg